Drug-Eluting Stents: Global Strategic Business Report

Global Drug-Eluting Stents Market to Reach $11.7 Billion by 2030

The global market for Drug-Eluting Stents estimated at US$7.3 Billion in the year 2022, is projected to reach a revised size of US$11.7 Billion by 2030, growing at a CAGR of 6% over the analysis period 2022-2030. Polymer-Free, one of the segments analyzed in the report, is projected to record 6.3% CAGR and reach US$7.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Polymer-based segment is readjusted to a revised 5.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $2 Billion, While China is Forecast to Grow at 9.9% CAGR

The Drug-Eluting Stents market in the U.S. is estimated at US$2 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 9.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.2% and 6.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Select Competitors (Total 33 Featured) -

• Abbott Laboratories
• AlviMedica
• Arterius Limited
• Biotronik SE
• Boston Scientific Corporation
• Cook Medical
• Medtronic plc
• STENTYS SA
• Terumo Corporation

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year